ClinicalTrials.gg

Program

HPP737

A development code. Also written as “HPP737 20mg”.

Its studies are mostly in Psoriasis, led by Newsoara Biopharma.

Furthest: phase 3, since Jul 7, 20264 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Newsoara Biopharma41 open or runningphase 3since Jul 7, 2026Aug 5, 2024none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 5, 2024First study: no phase study in PsoriasisFirst studyNCT06584058 · 8 planned · China
  2. Jul 6, 2026Phase 2 study in PsoriasisNCT07707141 · 123 enrolled · China
  3. Jul 7, 20262 phase 3 studies in PsoriasisPhase 3 reachedNCT07712731, NCT07712705

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07712731Psoriasis · China3CompletedApr 1, 2026607
NCT07712705Psoriasis · China3CompletedSep 29, 2023515
NCT07707141Psoriasis · China2CompletedDec 20, 2021123
NCT06584058Psoriasis · China–Not yet recruitingJul 30, 20258

How it is read

Names in the registry

  • “HPP737”, 3 entries
  • “HPP737 20mg”, 1 entry

Codes read as this program: HPP737.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.